The rationale for mTOR inhibition in epithelial ovarian cancer (Q37627253)

From Wikidata

Revision as of 04:01, 1 September 2024 by Emijrpbot (talk | contribs) (‎Changed label, description and/or aliases in es: BOT - Adding descriptions (1 languages): es)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on December 2009

Language	Label	Description	Also known as
English	The rationale for mTOR inhibition in epithelial ovarian cancer	scientific article published on December 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

The rationale for mTOR inhibition in epithelial ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

based on heuristic

inferred from title

author name string

Xuan Bich Trinh

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Peter A van Dam

2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Luc Y Dirix

3

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Peter B Vermeulen

4

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Wiebren A A Tjalma

5

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

language of work or name

0 references

publication date

1 December 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Expert Opinion on Investigational Drugs

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1885-1891

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Emerging drugs for ovarian cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Advanced epithelial ovarian cancer: 1998 consensus statements

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Molecular profiling of platinum resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Experience with bevacizumab in the management of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

The Akt-mTOR tango and its relevance to cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

mTOR, translation initiation and cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

mTOR and cancer: insights into a complex relationship

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Drug eluting stents: an updated meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

When translation meets transformation: the mTOR story

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

mTOR and P70 S6 kinase expression in primary liver neoplasms

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma c

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

PIK3CA is implicated as an oncogene in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Novel agents in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1517%2F13543780903321508

21 January 2018

Identifiers

10.1517/13543780903321508

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37627253&oldid=2241215052"